probenecid has been researched along with cefuroxime in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (38.89) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kokue, EI; Soback, S; Ziv, G | 1 |
| Baddour, LM; Cocchetto, DM; Gibbs, RS; Mertz, G; Noble, RC | 1 |
| Das, RP; Jones, K; Robinson, AJ; Timmins, DJ | 1 |
| Fong, IW; Hinton, NA; Linton, W; Simbul, M | 1 |
| Ansink-Schipper, MC; Michel, MF; Schift, R; Stolz, E; van Joost, T; van Ulsen, J; Woudstra, RK | 1 |
| Gottlieb, A; Mills, J | 1 |
| Mattie, H; Van Strijen, E; Verhagen, CA | 1 |
| Garton, AM; Gilpin, J; Marrelli, M; Rennie, RP; Shafran, SD | 1 |
| Desai, A; Mopkar, O; Rao, PP | 1 |
| Bingham, JS; Das, R; Oriel, JD; Ridgway, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Bommareddy, A; Gionfriddo, MR; Heindel, GA; Mukhija, P; Vanwert, AL; Witkowski, S; Wolman, AT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for probenecid and cefuroxime
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for probenecid and cefuroxime
| Article | Year |
|---|---|
Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated gonococcal infections in women.
Topics: Adolescent; Adult; Amoxicillin; Cefuroxime; Cephalosporins; Drug Therapy, Combination; Female; Gonorrhea; Humans; Middle Aged; Probenecid | 1989 |
Cefuroxime axetil to treat gonorrhea.
Topics: Ampicillin; Cefuroxime; Cephalosporins; Clinical Trials as Topic; Drug Therapy, Combination; Female; Gonorrhea; Humans; Male; Probenecid; Random Allocation | 1988 |
Comparative clinical efficacy of single oral doses of cefuroxime axetil and amoxicillin in uncomplicated gonococcal infections.
Topics: Amoxicillin; Cefuroxime; Cephalosporins; Drug Therapy, Combination; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae; Probenecid; Prospective Studies; Random Allocation | 1986 |
Comparison of oral treatment of uncomplicated urogenital and rectal gonorrhoea with cefuroxime axetil ester or clavulanic acid potentiated amoxycillin (Augmentin).
Topics: Administration, Oral; Adolescent; Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Cefuroxime; Cephalosporins; Clavulanic Acids; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Female; Gonorrhea; Humans; Male; Middle Aged; Probenecid; Random Allocation | 1986 |
Cefuroxime axetil for treatment of uncomplicated gonorrhea.
Topics: Adolescent; Adult; Aged; Amoxicillin; Cefuroxime; Cephalosporins; Drug Therapy, Combination; Gonorrhea; Humans; Male; Middle Aged; Probenecid; Random Allocation; Rectal Diseases; Urethritis | 1986 |
Comparative trial to evaluate the efficacy and tolerability of cefuroxime 250mg with probenecid 250mg with cefuroxime 500mg in the management of community acquired pneumonia, acute bronchitis and acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Bronchitis; Cefuroxime; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Pneumonia; Probenecid; Prospective Studies | 2000 |
11 other study(ies) available for probenecid and cefuroxime
| Article | Year |
|---|---|
Probenecid effect on cefuroxime pharmacokinetics in calves.
Topics: Animals; Cattle; Cefuroxime; Cephalosporins; Drug Interactions; Half-Life; Injections, Intramuscular; Injections, Intravenous; Male; Probenecid | 1989 |
The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion.
Topics: Administration, Oral; Adult; Ceftazidime; Cefuroxime; Humans; Injections, Intravenous; Kidney Tubules; Male; Probenecid | 1994 |
Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Cefuroxime; Cephalosporins; Drug Interactions; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Probenecid; Renal Agents | 1997 |
A comparative trial of cefuroxime axetil and ampicillin plus probenecid in the treatment of acute gonococcal infection.
Topics: Acute Disease; Ampicillin; Anti-Bacterial Agents; Cefuroxime; Clinical Trials as Topic; Drug Therapy, Combination; Female; Gonorrhea; Humans; Male; Probenecid | 1989 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Biological Transport; Cell Line, Transformed; Humans; Mice; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Solubility; Structure-Activity Relationship | 2013 |